Literature DB >> 30833345

Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1.

Mara Roxana Rubinstein1, Jung Eun Baik1, Stephen M Lagana2, Richard P Han3, William J Raab2, Debashis Sahoo4, Piero Dalerba2,5,6,7, Timothy C Wang6,7, Yiping W Han8,6,7,9.   

Abstract

Fusobacterium nucleatum, a Gram-negative oral anaerobe, is a significant contributor to colorectal cancer. Using an in vitro cancer progression model, we discover that F. nucleatum stimulates the growth of colorectal cancer cells without affecting the pre-cancerous adenoma cells. Annexin A1, a previously unrecognized modulator of Wnt/β-catenin signaling, is a key component through which F. nucleatum exerts its stimulatory effect. Annexin A1 is specifically expressed in proliferating colorectal cancer cells and involved in activation of Cyclin D1. Its expression level in colon cancer is a predictor of poor prognosis independent of cancer stage, grade, age, and sex. The FadA adhesin from F. nucleatum up-regulates Annexin A1 expression through E-cadherin. A positive feedback loop between FadA and Annexin A1 is identified in the cancerous cells, absent in the non-cancerous cells. We therefore propose a "two-hit" model in colorectal carcinogenesis, with somatic mutation(s) serving as the first hit, and F. nucleatum as the second hit exacerbating cancer progression after benign cells become cancerous. This model extends the "adenoma-carcinoma" model and identifies microbes such as F. nucleatum as cancer "facilitators".
© 2019 The Authors.

Entities:  

Keywords:  zzm321990Fusobacterium nucleatumzzm321990; Annexin A1; FadA; colorectal cancer; two‐hit model

Mesh:

Substances:

Year:  2019        PMID: 30833345      PMCID: PMC6446206          DOI: 10.15252/embr.201847638

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  44 in total

1.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.

Authors:  Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino
Journal:  Gut       Date:  2015-08-26       Impact factor: 23.059

Review 2.  Gastrointestinal malignancy and the microbiome.

Authors:  Maria T Abreu; Richard M Peek
Journal:  Gastroenterology       Date:  2014-01-07       Impact factor: 22.682

3.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.

Authors:  Susan Bullman; Chandra S Pedamallu; Ewa Sicinska; Thomas E Clancy; Xiaoyang Zhang; Diana Cai; Donna Neuberg; Katherine Huang; Fatima Guevara; Timothy Nelson; Otari Chipashvili; Timothy Hagan; Mark Walker; Aruna Ramachandran; Begoña Diosdado; Garazi Serna; Nuria Mulet; Stefania Landolfi; Santiago Ramon Y Cajal; Roberta Fasani; Andrew J Aguirre; Kimmie Ng; Elena Élez; Shuji Ogino; Josep Tabernero; Charles S Fuchs; William C Hahn; Paolo Nuciforo; Matthew Meyerson
Journal:  Science       Date:  2017-11-23       Impact factor: 47.728

4.  Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition.

Authors:  Yvonne L Chao; Christopher R Shepard; Alan Wells
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

5.  Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness.

Authors:  Y Shimoyama; A Nagafuchi; S Fujita; M Gotoh; M Takeichi; S Tsukita; S Hirohashi
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

6.  Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma.

Authors:  Udo Roth; Hanieh Razawi; Julia Hommer; Katja Engelmann; Tilo Schwientek; Stefan Müller; Stephan E Baldus; Georgios Patsos; Anthony P Corfield; Christos Paraskeva; Franz-Georg Hanisch
Journal:  Proteomics       Date:  2010-01       Impact factor: 3.984

Review 7.  The microbiome and cancer.

Authors:  Robert F Schwabe; Christian Jobin
Journal:  Nat Rev Cancer       Date:  2013-10-17       Impact factor: 60.716

8.  Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc.

Authors:  Jawad Abed; Johanna E M Emgård; Gideon Zamir; Mouhammad Faroja; Gideon Almogy; Amalie Grenov; Asaf Sol; Ronit Naor; Eli Pikarsky; Karine A Atlan; Anna Mellul; Stella Chaushu; Abigail L Manson; Ashlee M Earl; Nora Ou; Caitlin A Brennan; Wendy S Garrett; Gilad Bachrach
Journal:  Cell Host Microbe       Date:  2016-08-10       Impact factor: 21.023

9.  Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix.

Authors:  Leila Akkari; Vasilena Gocheva; Jemila C Kester; Karen E Hunter; Marsha L Quick; Lisa Sevenich; Hao-Wei Wang; Christoph Peters; Laura H Tang; David S Klimstra; Thomas Reinheckel; Johanna A Joyce
Journal:  Genes Dev       Date:  2014-10-01       Impact factor: 11.361

10.  Fusobacterium is associated with colorectal adenomas.

Authors:  Amber N McCoy; Félix Araújo-Pérez; Andrea Azcárate-Peril; Jen Jen Yeh; Robert S Sandler; Temitope O Keku
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

View more
  84 in total

Review 1.  Oral and intestinal bacterial exotoxins: Potential linked to carcinogenesis.

Authors:  Matthew Silbergleit; Adrian A Vasquez; Carol J Miller; Jun Sun; Ikuko Kato
Journal:  Prog Mol Biol Transl Sci       Date:  2020-04-09       Impact factor: 3.622

2.  Gut microbial differences in breast and prostate cancer cases from two randomised controlled trials compared to matched cancer-free controls.

Authors:  K S Smith; A D Frugé; W van der Pol; N E Caston; C D Morrow; W Demark-Wahnefried; T L Carson
Journal:  Benef Microbes       Date:  2021-04-01       Impact factor: 4.205

Review 3.  The microbiome and gynaecological cancer development, prevention and therapy.

Authors:  Paweł Łaniewski; Zehra Esra Ilhan; Melissa M Herbst-Kralovetz
Journal:  Nat Rev Urol       Date:  2020-02-18       Impact factor: 14.432

Review 4.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 5.  Gut microbiota-derived metabolites in CRC progression and causation.

Authors:  Nishu Dalal; Rekha Jalandra; Nitin Bayal; Amit K Yadav; Minakshi Sharma; Govind K Makharia; Pramod Kumar; Rajeev Singh; Pratima R Solanki; Anil Kumar
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-17       Impact factor: 4.553

6.  Association or Causation? Exploring the Oral Microbiome and Cancer Links.

Authors:  F R F Teles; F Alawi; R M Castilho; Y Wang
Journal:  J Dent Res       Date:  2020-08-18       Impact factor: 6.116

Review 7.  The bidirectional nature of microbiome-epithelial cell interactions.

Authors:  Angel G Solis; Max Klapholz; Jingru Zhao; Maayan Levy
Journal:  Curr Opin Microbiol       Date:  2020-07-09       Impact factor: 7.934

Review 8.  Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy.

Authors:  Runqi Zhu; Tianqun Lang; Wenlu Yan; Xiao Zhu; Xin Huang; Qi Yin; Yaping Li
Journal:  Adv Sci (Weinh)       Date:  2021-03-09       Impact factor: 16.806

Review 9.  Approaching precision medicine by tailoring the microbiota.

Authors:  Gaeun Ryu; Hyojin Kim; Ara Koh
Journal:  Mamm Genome       Date:  2021-03-01       Impact factor: 2.957

Review 10.  Role of gut microbiota in epigenetic regulation of colorectal Cancer.

Authors:  Yinghui Zhao; Chuanxin Wang; Ajay Goel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-13       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.